Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Hisse Senetlerindeki Sıralama #29796
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Hisse Fiyatı
$0.12027613
Piyasa Değeri
$19.61M
Değişim (1 gün)
-3.06%
Değişim (1 yıl)
-40.33%
Ülke
FR
Ticaret GenSight Biologics S.A. (SIGHT)

Kategori

GenSight Biologics S.A. (SIGHT) için kazanç
2026 itibarıyla kazanç TTM: 0
GenSight Biologics S.A. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
GenSight Biologics S.A. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR